Showing 7881-7890 of 8629 results for "".
- SPF30 Sunscreens Delay Melanoma Onset in Mouse Modelhttps://practicaldermatology.com/news/spf30-sunscreens-delay-melanoma-onset-in-mouse-model/2458601/Applying sun protection factor 30 (SPF30) sunscreen prior to exposure to ultraviolet-B (UVB) light delayed melanoma onset in a mouse model, report researchers from The Ohio State University Comprehensive Cancer Center Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. S
- Study on TRASER for Nasal Spider Veins Scores Top Honors from ASLMShttps://practicaldermatology.com/news/study-on-traser-for-nasal-spider-veins-scores-top-honors-from-aslms/2458606/Houston dermatologist Paul M. Friedman, MD won the Best of Cutaneous Applications Abstract Session Award for his paper on the use of a novel optical device to treat vexing nasal telangiectasias. The award was presented at the 2016 Annual Conference of the American S
- Recent AAD Meeting Boasts Record Attendancehttps://practicaldermatology.com/news/recent-aad-meeting-boasts-record-attendance/2458607/More than 18,500 people from 107 countries attended the American Academy of Dermatology’s 74th Annual Meeting held in Washington, DC in early March 2016. The meeting featured more than 375 educational sessions, during
- Avalere: Biosimilars More Expensive for Medicare Beneficiarieshttps://practicaldermatology.com/news/avalere-biosimilars-more-expensive-for-medicare-beneficiaries/2458610/Medicare beneficiaries are likely to pay more for biosimilars than for the biologic reference product in Part D under current law, according to a new report from
- Kourtney Kardashian is Manuka Doctor's New Brand Ambassadorhttps://practicaldermatology.com/news/kourtney-kardashian-is-manuka-doctors-new-brand-ambassador/2458614/Kybella has Khloe, and now Manuka Doctors got Kourtney. Kourtney Kardashian is the new face of Manuka Doctor, a skincare line comprising Manuka Honey and patented Purified Bee Venom.
- Alphaeon's Botulinum Toxin Meets Primary Endpoints in Two Phase III Trialshttps://practicaldermatology.com/news/alphaeons-botulinum-toxin-meets-primary-endpoints-in-two-phase-iii-trials/2458615/Alphaeon’s DWP-450 botulinum toxin type A achieved it primary endpoints in two Phase III trials reported at the American Society of Aesthetic Plastic Surgery meeting in Las Vegas. In the two phase III randomized, multi-center, placebo-controlled, double blind tria
- New from Suneva: Regenica® Rejuvenating Dual Serumhttps://practicaldermatology.com/news/new-from-suneva-regenica-rejuvenating-dual-serum/2458620/Suneva Medical, Inc., is rolling out Regenica® Rejuvenating Dual Serum, the newest addition to the Regenica® skin care line. The dual chamber serum is created via growth factor
- Topical RHA Technology Boosts Skin Rehydration, Rejuvenationhttps://practicaldermatology.com/news/topical-rha-technology-boosts-skin-rehydration-and-rejuvenation/2458621/Crosslinked resilient Hyaluronic Acid (RHA™) bests non-crosslinked (linear) low and high molecular weight hyaluronic acid at increasing water content of the skin, maintaining skin integrity and improving skin barrier function, new research suggests. The findings appear in the
- Rosacea Awareness Month Highlights Potential Increased Health Riskshttps://practicaldermatology.com/news/rosacea-awareness-month-highlights-potential-increased-health-risks/2458624/New studies are now revealing potential associations between rosacea and increased risks of cardiovascular disease, gastrointestinal disease, certain types of cancer and many other systemic illnesses. The National Rosacea Society (NRS) has designated April as Rosacea Awareness Month to alert the
- Next Stop FDA Approval? Dupilumab Improves Symptoms in Moderate-to-Severe ADhttps://practicaldermatology.com/news/next-stop-fda-approval-dupilumab-improves-symptoms-in-moderate-to-severe-ad/2458625/Dupilumab helps improve the signs and symptoms of moderate-to-severe atopic dermatitis (AD) in adults, according to two late stage clinical trials. The U.S. Food and Drug Administration (FDA) granted dupilumab Breakthrough Therapy designation in AD in November 2014. U.S. regulatory